Pharmacology review: Pharmacotherapy for gastroesophageal reflux disease

NeoReviews

Volumn 12, Issue 3, 2011, Pages

  Hibbs, Anna Maria ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959863922     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.12-3-e159     Document Type: Article

References (64)

1. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006; 117:1979-87
2. Dhillon AS, Ewer AK. Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 2004;93:88-93
3. Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotten CM. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics. 2008;121:22-27
4. Golski CA, Rome ES, Martin RJ, et al. Pediatric specialists' beliefs about gastroesophageal reflux disease in premature infants. Pediatrics. 2010;125:96-104
5. Clark RH, Spitzer AR. Patience is a virtue in the management of gastroesophageal reflux. J Pediatr. 2009;155:464-465
6. Rudolph CD. Supraesophageal complications of gastroesophageal reflux in children: challenges in diagnosis and treatment. Am J Med. 2003;115(suppl 3A):150S-156S
7. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(suppl 2):S1-S31
8. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278-1295
9. Vandenplas Y, Salvatore S, Hauser B. The diagnosis and management of gastrooesophageal reflux in infants. Early Hum Dev. 2005;81:1011-24
10. Slocum C, Hibbs AM, Martin RJ, Orenstein SR. Infant apnea and gastroesophageal reflux: a critical review and framework for further investigation. Curr Gastroenterol Rep. 2007;9:219-224
11. Jadcherla SR, Rudolph CD. Gastroesophageal reflux in the preterm neonate. NeoReviews. 2005;6:e87-e98
12. Orenstein SR. Tests to assess symptoms of gastroesophageal reflux in infants and children. J Pediatr Gastroenterol Nutr.2003; 37(suppl 1):S29-S32
13. Condino AA, Sondheimer J, Pan Z, Gralla J, Perry D, O'Connor JA. Evaluation of infantile acid and nonacid gastroesophageal reflux using combined pH monitoring and impedance measurement. J Pediatr Gastroenterol Nutr. 2006;42:16-21
14. Slocum C, Arko M, Di Fiore J, Martin RJ, Hibbs AM. Apnea, bradycardia and desaturation in preterm infants before and after feeding. J Perinatol. 2009;29:209-212
15. Di Fiore JM, Arko M, Whitehouse M, Kimball A, Martin RJ. Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. Pediatrics. 2005;116:1059-1063
16. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117:e137-e142
17. Carrion V, Egan EA. Prevention of neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 1990;11:317-323
18. Cothran DS, Borowitz SM, Sutphen JL, Dudley SM, Donowitz LG. Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol. 1997;17:383-388
19. Bianconi S, Gudavalli M, Sutija VG, Lopez AL, Barillas-Arias L, Ron N. Ranitidine and late-onset sepsis in the neonatal intensive care unit. J Perinat Med. 2007;35: 147-150
20. Apte NM, Karnad DR, Medhekar TP, Tilve GH, Morye S, Bhave GG. Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: a randomized, controlled trial. Crit Care Med. 1992;20:590-593
21. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care. 2002;17:240-245
22. Miano TA, Reichert MG, Houle TT, MacGregor DA, Kincaid EH, Bowton DL. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest. 2009;136:440-447
23. Sharma H, Singh D, Pooni P, Mohan U. A study of profile of ventilator-associated pneumonia in children in Punjab. J Trop Pediatr. 2009;55:393-395
24. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53(RR-3):1-36
25. Beaulieu M, Williamson D, Sirois C, Lachaine J. Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit? J Crit Care. 2008;23:513-518
26. Kobashi Y, Matsushima T. Clinical analysis of patients requiring long-term mechanical ventilation of over three months: ventilator-associated pneumonia as a primary complication. Intern Med. 2003;42: 25-32
27. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338:791-797
28. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817-e820
29. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet. 2000;39:295-309
30. Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastrooesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003;17:1097-1107
31. Cotton RB, Hazinski TA, Morrow JD, et al. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Res. 2006;59:795-800
32. Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr. 2009;155:516-521
33. Hu WH, Wang KY, Hwang DS, Ting CT, Wu TC. Histamine 2 receptor blockerranitidine and sinus node dysfunction. Zhonghua Yi Xue Za Zhi (Taipei). 1997;60:1-5
34. Alliet P, Devos E. Ranitidine-induced bradycardia in a neonate-secondary to congenital long QT interval syndrome? Eur J Pediatr. 1994;153:781
35. Hinrichsen H, Halabi A, Kirch W. Clinical aspects of cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol. 1995;35:107-116
36. Nahum E, Reish O, Naor N, Merlob P. Ranitidine-induced bradycardia in a neonate-a first report. Eur J Pediatr. 1993; 152:933-934
37. Ooie T, Saikawa T, Hara M, Ono H, Seike M, Sakata T. H2-blocker modulates heart rate variability. Heart Vessels. 1999;14: 137-142
38. Tanner LA, Arrowsmith JB. Bradycardia and H2 antagonists. Ann Intern Med. 1988;109:434-435
39. Yang J, Russell DA, Bourdeau JE. Case report: ranitidine-induced bradycardia in a patient with dextrocardia. Am J Med Sci. 1996;312:133-135
40. Di Fiore J, Arko M, Herynk B, Martin R, Hibbs AM. Characterization of cardiorespiratory events following gastroesophageal reflux in preterm infants. J Perinatol. 2010;30:683-687
41. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421-427
42. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebocontrolled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009; 154:514-520. e4
43. United States Food and Drug Administration. Proton Pump Inhibitors (PPI): Class Labeling Change. 2010. Accessed December 2010 at: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm213321.htm
44. United States Food and Drug Administration. Possible Increased Risk of Bone Freactures With Certain Antacid Drugs. 2010. Accessed December 2010 at: http://www. fda.gov/ForConsumers/ConsumerUpdates/ ucm213240.htm
45. Taylor AM; Pediatric Advisory Committee Meeting. United States Food and Drug Administration. Pediatric Focused Safety Review: Proton Pump Inhibitors: Esomeprazole, Lansoprazole, Omeprazole, Rabeprazole. 2010. Accessed December 2010 at: http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Pediatric AdvisoryCommittee/UCM216303.pdf
46. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170: 784-790
47. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170: 772-778
48. United States Food and Drug Administration. Propulsid (cisapride). 2000. Accessed December 2010 at: http://www.fda.gov/ Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm173074. htm
49. Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008; 153:663-666
50. Craig WR, Hanlon-Dearman A, Sinclair C, Taback S, Moffatt M. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev. 2004;4:CD003502
51. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics. 2006;118:746-752
52. United States Food and Drug Administration. Metoclopramide-containing Drugs. 2009. Accessed December 2010 at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm106942.htm
53. Madani S, Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol. 1997;24:79-81
54. Paturi B, Ryan RM, Michienzi KA, Lakshminrusimha S. Galactorrhea with metoclopramide use in the neonatal unit. J Perinatol. 2009;29:391-392
55. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf. 1996;15:261-273
56. Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol. 1984;247: G688-G694
57. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motorstimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother. 1984;26:863-869
58. Feighner SD, Tan CP, McKee KK, et al. Receptor for motilin identified in the human gastrointestinal system. Science. 1999;284:2184-2188
59. Ng E, Shah VS. Erythromycin for the prevention and treatment of feeding intolerance in preterm infants. Cochrane Database Syst Rev. 2008;3:CD001815
60. Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2005;90:F301-F306
61. Ng SC, Gomez JM, Rajadurai VS, Saw SM, Quak SH. Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. J Pediatr Gastroenterol Nutr. 2003;37:554-558
62. Ng PC. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants. Neonatology. 2009;95: 97-104
63. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(suppl 1):S71-S76
64. Simko J, Csilek A, Karaszi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection. 2008;36:194-206